A randomized, double blind, placebo-controlled, multicenter, phase III study comparing the activity of paclitaxel plus trastuzumab plus lapatinib to paclitaxel plus trastuzumab plus placebo in women with ErbB2 overexpressing metastatic breast cancer

Trial Profile

A randomized, double blind, placebo-controlled, multicenter, phase III study comparing the activity of paclitaxel plus trastuzumab plus lapatinib to paclitaxel plus trastuzumab plus placebo in women with ErbB2 overexpressing metastatic breast cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs Lapatinib (Primary) ; Paclitaxel; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 26 Jan 2017 Planned End Date changed from 1 Mar 2017 to 31 Dec 2017.
    • 27 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Mar 2017.
    • 25 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top